XTX Markets’s Akebia Therapeutics AKBA Stock Holding History

XTX Markets’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12,302	Closed	-$31K	–	194
2020 Q3	$31K	Buy	+12,302	New	+$108K	0.15%	95

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

XTX Markets's AKBA Position: Q4 2020 in Review

XTX Markets sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 12,302 shares — an estimated $31K sold.

XTX Markets first reported a position in AKBA in Q3 2020 and held it in 1 quarter. The position peaked at $31K in Q3 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

XTX Markets reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
XTX Markets sold 12,302 Akebia Therapeutics shares in Q4 2020, an estimated $31K.
XTX Markets first reported a position in Akebia Therapeutics in Q3 2020 and held it in 1 quarter.
XTX Markets's Akebia Therapeutics position peaked at $31K in Q3 2020.
143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.